Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Granite Point Capital and Marinus Pharmaceuticals Inc (MRNS)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Granite Point Capital Master Fund 0 1,063,790 0 1,063,790 1,063,790 4.74%
Granite Point Capital Panacea Global Healthcare Fund 0 653,266 0 653,266 653,266 2.91%
Granite Point Capital Scorpion Focused Ideas Fund 0 467,792 0 467,792 467,792 2.09%
Granite Point Capital 0 2,184,848 0 2,184,848 2,184,848 9.75%
Granite Point Capital Management 0 2,184,848 0 2,184,848 2,184,848 9.75%
Warren B. Lammert, III 0 2,184,848 0 2,184,848 2,184,848 9.75%
Warren Lammert
Warren Lammert
Granite Point Capital

Page 1 of 13 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*

Marinus Pharmaceuticals,
Inc.

(Name of Issuer)

Common Stock,
$0.001 par value

(Title of Class of Securities)

56854Q101

(CUSIP Number)

July 6, 2017

(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
ý Rule 13d-1(c)
¨ Rule 13d-1(d)
(Page 1 of 13 Pages)

______________________________

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act“) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).

Follow Marinus Pharmaceuticals Inc (NASDAQ:MRNS)
Trade (NASDAQ:MRNS) Now!